Product Details
| Product Name:
Leminoprazole |
CAS No.:
104340-86-5 |
| Purity:
99.56% |
Supply Ability:
10g |
| Release date:
2025/11/11 |
Product Introduction
Bioactivity
| Name | Leminoprazole |
| Description | Leminoprazole is an orally available H+,K(+)-ATPase inhibitor that protects gastric mucosal cells from various cellular damages. |
| In vitro | Leminoprazole, when given orally at doses of 10-100 mg/kg, was able to dose-dependently inhibit H+, K(+)-ATPase activity at 3 and 6 hours after administration. Specifically, Leminoprazole (60 mg/kg, p.o.) inhibited H+, K(+)-ATPase for a much longer duration than omeprazole (30 mg/kg, p.o.). In pylorus ligated rats, the inhibitory effect of Leminoprazole on gastric acid secretion and its inhibitory rate on H+, K(+)-ATPase activity showed a good correlation, suggesting that the inhibitory efficacy of Leminoprazole in inhibiting gastric acid secretion via H+, K(+)-ATPase activity is comparable to that of omeprazole. The inhibitory effect was comparable to that of omeprazole. In addition, Leminoprazole (100 mg/kg) directly inhibited H+, K(+)-ATPase activity even when administered intragastrically after pyloric ligation, demonstrating the ability of this compound to inhibit H+, K(+)-ATPase activity directly from the gastric lumen. Further studies showed that continuous administration of Leminoprazole (100 mg/kg, p.o.) for 2 or 4 weeks had the same inhibitory effect on H+, K(+)-ATPase as a single dose. |
| In vivo | Leminoprazole, when given orally at doses of 10-100 mg/kg, was able to dose-dependently inhibit H+, K(+)-ATPase activity at 3 and 6 hours after administration. Specifically, Leminoprazole (60 mg/kg, p.o.) inhibited H+, K(+)-ATPase for a much longer duration than omeprazole (30 mg/kg, p.o.). In pylorus ligated rats, the inhibitory effect of Leminoprazole on gastric acid secretion and its inhibitory rate on H+, K(+)-ATPase activity showed a good correlation, suggesting that the inhibitory efficacy of Leminoprazole in inhibiting gastric acid secretion via H+, K(+)-ATPase activity is comparable to that of omeprazole. The inhibitory effect was comparable to that of omeprazole. In addition, Leminoprazole (100 mg/kg) directly inhibited H+, K(+)-ATPase activity even when administered intragastrically after pyloric ligation, demonstrating the ability of this compound to inhibit H+, K(+)-ATPase activity directly from the gastric lumen. Further studies showed that continuous administration of Leminoprazole (100 mg/kg, p.o.) for 2 or 4 weeks had the same inhibitory effect on H+, K(+)-ATPase as a single dose. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (146.43 mM), Sonication is recommended.
|
| Keywords | Leminoprazole | H+/K+-ATPase |
| Inhibitors Related | Tirofiban hydrochloride monohydrate | Sodium oleate | Ciclopirox | Chebulinic acid | trans-Aconitic acid | Phlorizin | Ginsenoside Rb1 | Chlorpropamide | Revaprazan hydrochloride | Oleic acid | Esomeprazole Sodium | Trichlormethiazide |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2375-03-3
$39.00 / 10mg
-
CAS:2890188-81-3
$64.00 / 5mg
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States